2023
Role of the immune-kynurenine pathway in treatment-resistant schizophrenia
Chen W, Tian Y, Gou M, Wang L, Tong J, Zhou Y, Feng W, Li Y, Chen S, Liu Y, Wang Z, Pan S, Zhang P, Huang J, Yang X, Li C, Tian L, Hong L, Tan Y. Role of the immune-kynurenine pathway in treatment-resistant schizophrenia. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2023, 130: 110926. PMID: 38147973, DOI: 10.1016/j.pnpbp.2023.110926.Peer-Reviewed Original ResearchConceptsImmune-inflammatory response systemTreatment-resistant schizophreniaQUIN/KYNA ratioNon-TRS patientsHealthy controlsKynurenine pathwayKP metabolismKP activationKynurenic acidQuinolinic acidInflammation-related effectsPeripheral immune responseAnti-inflammatory cytokinesPro-inflammatory cytokinesBinary logistic regression analysisPathophysiology of schizophreniaLogistic regression analysisAge of onsetLower kynurenineKP metabolitesKYNA levelsIllness onsetPlasma levelsRisk factorsNMDA receptors
2020
Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★
Huang J, Zhu Y, Fan F, Chen S, Hong Y, Cui Y, Luo X, Tan S, Wang Z, Shang L, Yuan Y, Zhang J, Yang F, Li CR, Rowland LM, Kochunov P, Zhang F, Hong LE, Tan Y. Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★. Psychiatry Research Neuroimaging 2020, 297: 111043. PMID: 32062167, PMCID: PMC7490244, DOI: 10.1016/j.pscychresns.2020.111043.Peer-Reviewed Original ResearchTreatment-resistant schizophreniaTreatment-responsive patientsHippocampal volumeHealthy controlsSmaller total hippocampal volumesSmaller hippocampal volumesTotal hippocampal volumeAvailable antipsychotic medicationsSevere cognitive dysfunctionLogistic regression analysisSubgroup of schizophreniaGlobal cognitive deficitsCognitive domain deficitsSpecific deficitsAntipsychotic medicationCognitive dysfunctionTreatment resistanceHigh riskHC groupPatientsMemory deficitsCognitive deficitsCognitive functionSchizophreniaSignificant deficits